Background:

Melanoma-associated antigens recognized by cytotoxic T lymphocytes (CTL) have been grouped into three categories: melanocyte differentiation antigens, cancer/testis-specific antigens and mutated or aberrantly expressed antigens. Many of these antigens consist of peptides that are presented to T cells by HLA molecules; they represent potential targets for cancer immunotherapy. Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients.

Specificity:

MelanA polyclonal antibody detects endogenous levels of MelanA protein.

Alternative names:

MLANA, Antigen LB39 AA, Antigen LB39-AA, Antigen SK29 AA, Antigen SK29-AA, MAR1, MART 1, MART-1, MART1, Melan A, Melan A protein, Melanoma antigen recognized by T cells 1, Melanoma antigen recognized by T-cells 1, MLAN A, MLANA, OTTHUMP00000021036, OTTHUMP00000021037, OTTHUMP00000021038, Protein Melan-A,

Species reactivity:

Human

Host:

Rabbit

Ig type:

Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Immunogen:

recombinant protein

Purification & Purity:

ProA affinity purified

Molecular weight:

20 kDa

Applications:

WB IHC FC

Usage:

WB:1:1,000-1:2,000 FC:1:50-1:100 IHC:1:50-1:200

Storage:

Store at +4°C after thawing. Aliquot store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Precautions:

For research use only, not for use in diagnostic procedure.

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com